451 related articles for article (PubMed ID: 27870570)
1. Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors.
Ferrarotto R; Mitani Y; Diao L; Guijarro I; Wang J; Zweidler-McKay P; Bell D; William WN; Glisson BS; Wick MJ; Kapoun AM; Patnaik A; Eckhardt G; Munster P; Faoro L; Dupont J; Lee JJ; Futreal A; El-Naggar AK; Heymach JV
J Clin Oncol; 2017 Jan; 35(3):352-360. PubMed ID: 27870570
[TBL] [Abstract][Full Text] [Related]
2. Diffuse Staining for Activated NOTCH1 Correlates With NOTCH1 Mutation Status and Is Associated With Worse Outcome in Adenoid Cystic Carcinoma.
Sajed DP; Faquin WC; Carey C; Severson EA; H Afrogheh A; A Johnson C; Blacklow SC; Chau NG; Lin DT; Krane JF; Jo VY; Garcia JJ; Sholl LM; Aster JC
Am J Surg Pathol; 2017 Nov; 41(11):1473-1482. PubMed ID: 28914715
[TBL] [Abstract][Full Text] [Related]
3. Alterations of Notch pathway in patients with adenoid cystic carcinoma of the trachea and its impact on survival.
Xie M; Wei S; Wu X; Li X; You Y; He C
Lung Cancer; 2018 Jul; 121():41-47. PubMed ID: 29858025
[TBL] [Abstract][Full Text] [Related]
4. Association between high expression of phosphorylated Akt and mammalian target of rapamycin and improved survival in salivary gland adenoid cystic carcinoma.
Ouyang DQ; Liang LZ; Ke ZF; Zheng GS; Weng DS; Yang WF; Su YX; Liao GQ
Head Neck; 2017 Jun; 39(6):1145-1154. PubMed ID: 28230926
[TBL] [Abstract][Full Text] [Related]
5. Molecular Profiling and the Impact of Treatment on Outcomes in Adenoid Cystic Carcinoma Type I and II.
Hanna GJ; Grover P; Elliott A; McGrath J; Xiu J; Sukari A; Johnson JM; Wise-Draper T
Clin Cancer Res; 2024 May; 30(10):2225-2232. PubMed ID: 38416410
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of 1p36 locus deletion in adenoid cystic carcinoma of the salivary glands.
Šteiner P; Andreasen S; Grossmann P; Hauer L; Vaněček T; Miesbauerová M; Santana T; Kiss K; Slouka D; Skálová A
Virchows Arch; 2018 Oct; 473(4):471-480. PubMed ID: 29619555
[TBL] [Abstract][Full Text] [Related]
7. Morphological heterogeneity of oral salivary gland carcinomas: a clinicopathologic study of 41 cases with long term follow-up emphasizing the overlapping spectrum of adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma.
Schwarz S; Müller M; Ettl T; Stockmann P; Zenk J; Agaimy A
Int J Clin Exp Pathol; 2011 Apr; 4(4):336-48. PubMed ID: 21577319
[TBL] [Abstract][Full Text] [Related]
8. High frequency of loss of PTEN expression in human solid salivary adenoid cystic carcinoma and its implication for targeted therapy.
Liu H; Du L; Wang R; Wei C; Liu B; Zhu L; Liu P; Liu Q; Li J; Lu SL; Xiao J
Oncotarget; 2015 May; 6(13):11477-91. PubMed ID: 25909167
[TBL] [Abstract][Full Text] [Related]
9. Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes and Identifies Therapeutic Targets.
Ferrarotto R; Mitani Y; McGrail DJ; Li K; Karpinets TV; Bell D; Frank SJ; Song X; Kupferman ME; Liu B; Lee JJ; Glisson BS; Zhang J; Aster JC; Lin SY; Futreal PA; Heymach JV; El-Naggar AK
Clin Cancer Res; 2021 Feb; 27(3):852-864. PubMed ID: 33172898
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of Notch1 receptor and clinicopathological High-Risk Predictors in lacrimal gland adenoid cystic carcinoma.
Anjum S; Sen S; Pushker N; Bajaj MS; Kashyap S; Bakhshi S; Chosdol K; Meel R; Sharma MC
Acta Ophthalmol; 2021 Dec; 99(8):e1467-e1473. PubMed ID: 33675181
[TBL] [Abstract][Full Text] [Related]
11. Identification of methylated genes in salivary gland adenoid cystic carcinoma xenografts using global demethylation and methylation microarray screening.
Ling S; Rettig EM; Tan M; Chang X; Wang Z; Brait M; Bishop JA; Fertig EJ; Considine M; Wick MJ; Ha PK
Int J Oncol; 2016 Jul; 49(1):225-34. PubMed ID: 27212063
[TBL] [Abstract][Full Text] [Related]
12. RASSF1A promoter hypermethylation is a strong biomarker of poor survival in patients with salivary adenoid cystic carcinoma in a Chinese population.
Zhang CY; Zhao YX; Xia RH; Han J; Wang BS; Tian Z; Wang LZ; Hu YH; Li J
PLoS One; 2014; 9(10):e110159. PubMed ID: 25302792
[TBL] [Abstract][Full Text] [Related]
13. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study.
Hotte SJ; Winquist EW; Lamont E; MacKenzie M; Vokes E; Chen EX; Brown S; Pond GR; Murgo A; Siu LL
J Clin Oncol; 2005 Jan; 23(3):585-90. PubMed ID: 15659505
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact.
Locati LD; Perrone F; Cortelazzi B; Bergamini C; Bossi P; Civelli E; Morosi C; Lo Vullo S; Imbimbo M; Quattrone P; Dagrada GP; Granata R; Resteghini C; Mirabile A; Alfieri S; Orlandi E; Mariani L; Saibene G; Pilotti S; Licitra L
Eur J Cancer; 2016 Dec; 69():158-165. PubMed ID: 27821319
[TBL] [Abstract][Full Text] [Related]
15. MYB rearrangement and clinicopathologic characteristics in head and neck adenoid cystic carcinoma.
Rettig EM; Tan M; Ling S; Yonescu R; Bishop JA; Fakhry C; Ha PK
Laryngoscope; 2015 Sep; 125(9):E292-9. PubMed ID: 25963073
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC.
Chau NG; Hotte SJ; Chen EX; Chin SF; Turner S; Wang L; Siu LL
Ann Oncol; 2012 Jun; 23(6):1562-70. PubMed ID: 22080184
[TBL] [Abstract][Full Text] [Related]
17. Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01).
Kim Y; Lee SJ; Lee JY; Lee SH; Sun JM; Park K; An HJ; Cho JY; Kang EJ; Lee HY; Kim J; Keam B; Kim HR; Lee KE; Choi MY; Lee KH; Ahn MJ
Cancer; 2017 Jun; 123(11):1958-1964. PubMed ID: 28102887
[TBL] [Abstract][Full Text] [Related]
18. Analysis and significance of c-MET expression in adenoid cystic carcinoma of the salivary gland.
Bell D; Ferrarotto R; Fox MD; Roberts D; Hanna EY; Weber RS; El-Naggar AK
Cancer Biol Ther; 2015; 16(6):834-8. PubMed ID: 25923130
[TBL] [Abstract][Full Text] [Related]
19. Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.
Stoeck A; Lejnine S; Truong A; Pan L; Wang H; Zang C; Yuan J; Ware C; MacLean J; Garrett-Engele PW; Kluk M; Laskey J; Haines BB; Moskaluk C; Zawel L; Fawell S; Gilliland G; Zhang T; Kremer BE; Knoechel B; Bernstein BE; Pear WS; Liu XS; Aster JC; Sathyanarayanan S
Cancer Discov; 2014 Oct; 4(10):1154-67. PubMed ID: 25104330
[TBL] [Abstract][Full Text] [Related]
20. Detection of MYB Alterations and Other Immunohistochemical Markers in Primary Cutaneous Adenoid Cystic Carcinoma.
North JP; McCalmont TH; Fehr A; van Zante A; Stenman G; LeBoit PE
Am J Surg Pathol; 2015 Oct; 39(10):1347-56. PubMed ID: 26076064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]